Literature DB >> 23318001

Parkinson's disease in the nuclear age of neuroinflammation.

Yvonne M Nolan1, Aideen M Sullivan, André Toulouse.   

Abstract

Chronic neuroinflammation is associated with the pathophysiology of Parkinson's disease, a movement disorder characterised by deterioration of the nigrostriatal system of the brain. Recent studies have yielded important insights into the regulation of inflammation by nuclear receptors, a superfamily of ligand-activated transcription factors. Certain nuclear receptors are also emerging as regulators of neurodegeneration, including the degeneration of dopaminergic neurons in Parkinson's disease, and the importance of transcriptional control in this process is becoming increasingly apparent. Here, we discuss the role of Nurr1, peroxisome proliferator-activated receptors (PPARs), retinoic acid receptors, and glucocorticoid receptors in neuroinflammatory processes that contribute to dopaminergic neuronal degeneration. We examine current evidence providing insight into the potential of these important players as therapeutic targets for Parkinson's disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318001     DOI: 10.1016/j.molmed.2012.12.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  39 in total

Review 1.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

2.  Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs.

Authors:  Ingo Vogt; Jeanette Prinz; Mónica Campillos
Journal:  Genome Med       Date:  2014-08-17       Impact factor: 11.117

Review 3.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

Review 4.  The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.

Authors:  Yan Shen; Xingfang Guo; Chao Han; Fang Wan; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Zhicheng Lin; Jinsha Huang; Nian Xiong; Tao Wang
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261

5.  The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB.

Authors:  Briana R De Miranda; Katriana A Popichak; Sean L Hammond; Bryce A Jorgensen; Aaron T Phillips; Stephen Safe; Ronald B Tjalkens
Journal:  Mol Pharmacol       Date:  2015-04-09       Impact factor: 4.436

6.  Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.

Authors:  Briana R De Miranda; Katriana A Popichak; Sean L Hammond; James A Miller; Stephen Safe; Ronald B Tjalkens
Journal:  Toxicol Sci       Date:  2014-11-17       Impact factor: 4.849

7.  Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models.

Authors:  Daniela Lecca; Elzbieta Janda; Giovanna Mulas; Andrea Diana; Concetta Martino; Fabrizio Angius; Stefano Spolitu; Maria Antonietta Casu; Gabriella Simbula; Laura Boi; Barbara Batetta; Saturnino Spiga; Anna R Carta
Journal:  Br J Pharmacol       Date:  2018-07-12       Impact factor: 8.739

8.  Contra-directional Coupling of Nur77 and Nurr1 in Neurodegeneration: A Novel Mechanism for Memantine-Induced Anti-inflammation and Anti-mitochondrial Impairment.

Authors:  Xiaobo Wei; Huimin Gao; Jing Zou; Xu Liu; Dan Chen; Jinchi Liao; Yunqi Xu; Long Ma; Beisha Tang; Zhuohua Zhang; Xiang Cai; Kunling Jin; Ying Xia; Qing Wang
Journal:  Mol Neurobiol       Date:  2015-10-26       Impact factor: 5.590

9.  APOE genotype-dependent modulation of astrocyte chemokine CCL3 production.

Authors:  Eiron Cudaback; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Glia       Date:  2014-08-04       Impact factor: 7.452

Review 10.  Inflammatory mediators as biomarkers in brain disorders.

Authors:  Domenico Nuzzo; Pasquale Picone; Luca Caruana; Sonya Vasto; Annalisa Barera; Calogero Caruso; Marta Di Carlo
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.